Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Work In Process (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 11 years of Work In Process data on record, last reported at $42.5 million in Q3 2025.

  • For Q3 2025, Work In Process rose 17.89% year-over-year to $42.5 million; the TTM value through Sep 2025 reached $42.5 million, up 17.89%, while the annual FY2024 figure was $32.8 million, 6.44% up from the prior year.
  • Work In Process reached $42.5 million in Q3 2025 per AMPH's latest filing, down from $43.6 million in the prior quarter.
  • Across five years, Work In Process topped out at $43.8 million in Q1 2025 and bottomed at $28.3 million in Q3 2023.
  • Average Work In Process over 5 years is $36.3 million, with a median of $36.0 million recorded in 2024.
  • Peak YoY movement for Work In Process: dropped 26.63% in 2023, then skyrocketed 31.34% in 2025.
  • A 5-year view of Work In Process shows it stood at $33.3 million in 2021, then increased by 11.39% to $37.1 million in 2022, then decreased by 16.9% to $30.8 million in 2023, then rose by 6.44% to $32.8 million in 2024, then grew by 29.42% to $42.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Work In Process were $42.5 million in Q3 2025, $43.6 million in Q2 2025, and $43.8 million in Q1 2025.